​

EyePoint Pharmaceuticals Ownership | Who Owns EyePoint Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

EyePoint Pharmaceuticals Ownership Summary

EyePoint Pharmaceuticals is owned by 22.27% institutional investors, 3.67% insiders, and 74.06% retail investors. Suvretta capital management is the largest institutional shareholder, holding 9.99% of EYPT shares. Federated Hermes Kaufmann R is the top mutual fund, with 3.32% of its assets in EyePoint Pharmaceuticals shares.

EYPT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEyePoint Pharmaceuticals22.27%3.67%74.06%
SectorHealthcare Stocks 35.58%11.87%52.55%
IndustryBiotech Stocks 35.75%11.83%52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management8.30M9.99%$106.94M
Cormorant asset management, lp8.27M9.95%$106.54M
Blackrock funding, inc. /de7.18M8.64%$92.52M
Blackrock3.76M7.12%$32.75M
Vanguard group4.82M6.87%$88.10M
Federated hermes5.67M6.83%$73.08M
Franklin resources5.05M6.08%$65.08M
Janus henderson group3.60M4.34%$46.42M
Adage capital partners gp3.30M3.97%$42.54M
Paradigm biocapital advisors lp3.14M3.78%$40.51M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Principia wealth advisory530.73K6.06%$9.70M
Essex woodlands management1.08M5.58%$13.98M
Rosalind advisors1.04M5.37%$13.36M
Cormorant asset management, lp8.27M5.35%$106.54M
5am venture management1.05M3.76%$13.53M
Blue owl capital lp912.59K3.16%$11.76M
Suvretta capital management8.30M2.73%$106.94M
Artia global partners lp767.10K2.18%$9.89M
Commodore capital lp2.83M2.11%$36.41M
Stempoint capital lp810.76K2.03%$10.45M

Top Buyers

HolderShares% AssetsChange
Commodore capital lp2.83M2.11%2.83M
Citadel advisors1.91M0.00%1.91M
Eventide asset management1.25M0.27%1.25M
Vanguard group4.82M0.00%1.03M
Blackrock3.76M0.00%977.52K

Top Sellers

HolderShares% AssetsChange
Tcg crossover management---3.57M
Ra capital management---3.18M
Perceptive advisors---1.54M
Adage capital partners gp3.30M0.07%-1.40M
Orbimed advisors1.07M0.27%-1.40M

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp2.83M2.11%2.83M$36.41M
Eventide asset management1.25M0.27%1.25M$16.06M
Sio capital management721.78K1.33%721.78K$9.30M
Vanguard fiduciary trust504.47K0.00%504.47K$6.50M
Walleye capital300.18K0.02%300.18K$3.87M

Sold Out

HolderChange
Assetmark-15.00
Continuum advisory-16.00
Coldstream capital management-21.00
Park place capital-23.00
Principal securities-24.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202684-51.45%18,494,025-77.84%220.16%46-54.46%20-48.72%
Dec 31, 2025112-30.00%40,465,600-42.11%570.58%64-15.79%24-46.67%
Sep 30, 20251569.86%65,594,5981.78%931.10%767.04%4322.86%
Jun 30, 2025147-5.16%68,901,914-5.62%980.90%71-12.35%38-15.56%
Mar 31, 20251574.67%74,070,140-0.48%1060.57%81-16.49%4691.67%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Federated Hermes Kaufmann R2.77M3.32%-
Federated Hermes Kaufmann Growth2.77M3.32%-
Vanguard Total Stock Mkt Idx Inv2.60M3.10%-
Federated Hermes Kaufmann Small Cap A1.98M2.38%-
Federated Hermes Kaufmann Small Cap Grow1.98M2.38%-
Franklin Biotechnology Discv A(acc)USD1.92M2.30%-194.25K
Vanguard US Total Market Shares ETF1.56M2.27%-
iShares Russell 2000 ETF1.82M2.18%15.32K
Franklin Small Cap Growth Adv1.51M1.80%63.61K
Franklin US Small Cap Growth Equity1.44M1.73%160.91K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 17, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.55K
Mar 16, 2026Duker Jay S. President and CEOBuy$19.72K
Mar 04, 2026Ribeiro Ramiro Chief Medical OfficerSell$43.57K
Feb 17, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.55K
Jan 05, 2026Ribeiro Ramiro Chief Medical OfficerSell$727.32K

Insider Transactions Trends

DateBuySell
2026 Q2-1
2026 Q113
2025 Q4-5
2025 Q3--
2025 Q24-

EYPT Ownership FAQ

Who Owns EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals shareholders are primarily institutional investors at 22.27%, followed by 3.67% insiders and 74.06% retail investors. The average institutional ownership in EyePoint Pharmaceuticals's industry, Biotech Stocks , is 35.75%, which EyePoint Pharmaceuticals falls below.

Who owns the most shares of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals’s largest shareholders are Suvretta capital management (8.3M shares, 9.99%), Cormorant asset management, lp (8.26M shares, 9.95%), and Blackrock funding, inc. /de (7.18M shares, 8.64%). Together, they hold 28.59% of EyePoint Pharmaceuticals’s total shares outstanding.

Does Blackrock own EyePoint Pharmaceuticals?

Yes, BlackRock owns 7.12% of EyePoint Pharmaceuticals, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.75M$. In the last quarter, BlackRock increased its holdings by 977.52K shares, a 35.07% change.

Who is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Principia wealth advisory is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.06% of its assets in 530.72K EyePoint Pharmaceuticals shares, valued at 9.7M$.

Who is the top mutual fund holder of EyePoint Pharmaceuticals shares?

Federated Hermes Kaufmann R is the top mutual fund holder of EyePoint Pharmaceuticals shares, with 3.32% of its total shares outstanding invested in 2.77M EyePoint Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools